Mili Rohilla
Worcester, MANPI 1427629765
Payments from drug & device makers
$1,945in general payments, 2019–2025
Across 74 payments — averaging $26.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$364
- E.r. Squibb & Sons, L.L.C.$315
- Merck$237
- Gilead$195
- AstraZeneca$190
- Mirati Therapeutics, Inc.$95
- plus $549 from 14 others
What the payments were for
- Food & beverage$1,945100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 13 | $364 |
| E.r. Squibb & Sons, L.L.C. | 15 | $315 |
| Merck | 8 | $237 |
| Gilead | 7 | $195 |
| AstraZeneca | 7 | $190 |
| Mirati Therapeutics, Inc. | 3 | $95 |
| Seagen Inc. | 3 | $85 |
| Johnson & Johnson | 2 | $64 |
| Geron Corporation | 2 | $61 |
| AbbVie | 2 | $55 |
| Karyopharm Therapeutics Inc. | 2 | $40 |
| Incyte Corporation | 2 | $37 |
| GSK | 1 | $35 |
| Blue Earth Diagnostics | 1 | $33 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Pfizer | 1 | $27 |
| CTI Biopharma Corp. | 1 | $25 |
| Biogen | 1 | $22 |
| Boehringer Ingelheim | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.